NutraLife BioSciences, Inc.
NLBS
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 115.10K | 55.80K | 80.50K | 380.50K | 70.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 115.10K | 55.80K | 80.50K | 380.50K | 70.70K |
| Cost of Revenue | 20.60K | 4.70K | 123.10K | 367.20K | 43.60K |
| Gross Profit | 94.60K | 51.20K | -42.60K | 13.30K | 27.10K |
| SG&A Expenses | 422.60K | 639.50K | 601.70K | 656.60K | 503.30K |
| Depreciation & Amortization | 61.90K | 61.90K | 84.10K | 21.30K | 33.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 505.00K | 706.10K | 808.90K | 1.05M | 580.60K |
| Operating Income | -389.90K | -650.20K | -728.40K | -664.70K | -509.90K |
| Income Before Tax | -1.18M | -900.40K | -1.08M | -1.79M | -688.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.18M | -900.40K | -1.08M | -1.79M | -688.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.18M | -900.40K | -1.08M | -1.79M | -688.30K |
| EBIT | -389.90K | -650.20K | -728.40K | -664.70K | -509.90K |
| EBITDA | -328.00K | -588.40K | -644.30K | -643.30K | -476.20K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 175.72M | 175.12M | 173.50M | 171.40M | 167.75M |
| Average Diluted Shares Outstanding | 175.72M | 175.12M | 173.50M | 171.40M | 167.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
